These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 9562524)

  • 1. The beta-hexosaminidase deficiency disorders: development of a clinical paradigm in the mouse.
    Tifft CJ; Proia RL
    Ann Med; 1997 Dec; 29(6):557-61. PubMed ID: 9562524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biology and potential strategies for the treatment of GM2 gangliosidoses.
    Chavany C; Jendoubi M
    Mol Med Today; 1998 Apr; 4(4):158-65. PubMed ID: 9572057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
    Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
    Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent advances in molecular genetics of GM2 gangliosidosis].
    Wakamatsu N
    Nihon Rinsho; 1995 Dec; 53(12):2988-93. PubMed ID: 8577047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.
    Sango K; Yamanaka S; Hoffmann A; Okuda Y; Grinberg A; Westphal H; McDonald MP; Crawley JN; Sandhoff K; Suzuki K; Proia RL
    Nat Genet; 1995 Oct; 11(2):170-6. PubMed ID: 7550345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.
    Tsuji D; Higashine Y; Matsuoka K; Sakuraba H; Itoh K
    Clin Chim Acta; 2007 Mar; 378(1-2):38-41. PubMed ID: 17196574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical consequences of mutations causing the GM2 gangliosidoses.
    Mahuran DJ
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):105-38. PubMed ID: 10571007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and molecular aspects of late-onset GM2-gangliosidosis: B1 variant as a prototype.
    Suzuki K; Vanier MT
    Dev Neurosci; 1991; 13(4-5):288-94. PubMed ID: 1840099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment.
    Liu Y; Hoffmann A; Grinberg A; Westphal H; McDonald MP; Miller KM; Crawley JN; Sandhoff K; Suzuki K; Proia RL
    Proc Natl Acad Sci U S A; 1997 Jul; 94(15):8138-43. PubMed ID: 9223328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease.
    Yamanaka S; Johnson MD; Grinberg A; Westphal H; Crawley JN; Taniike M; Suzuki K; Proia RL
    Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9975-9. PubMed ID: 7937929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease.
    Cohen-Tannoudji M; Marchand P; Akli S; Sheardown SA; Puech JP; Kress C; Gressens P; Nassogne MC; Beccari T; Muggleton-Harris AL
    Mamm Genome; 1995 Dec; 6(12):844-9. PubMed ID: 8747922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
    Tsuji D
    Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biochemistry of HEXA and HEXB gene mutations causing GM2 gangliosidosis.
    Mahuran DJ
    Biochim Biophys Acta; 1991 Feb; 1096(2):87-94. PubMed ID: 1825792
    [No Abstract]   [Full Text] [Related]  

  • 14. The biochemical basis of gangliosidoses.
    Sandhoff K; Conzelmann E
    Neuropediatrics; 1984 Sep; 15 Suppl():85-92. PubMed ID: 6242704
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversibility of neuropathology in Tay-Sachs-related diseases.
    Cachón-González MB; Wang SZ; Ziegler R; Cheng SH; Cox TM
    Hum Mol Genet; 2014 Feb; 23(3):730-48. PubMed ID: 24057669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.
    Phaneuf D; Wakamatsu N; Huang JQ; Borowski A; Peterson AC; Fortunato SR; Ritter G; Igdoura SA; Morales CR; Benoit G; Akerman BR; Leclerc D; Hanai N; Marth JD; Trasler JM; Gravel RA
    Hum Mol Genet; 1996 Jan; 5(1):1-14. PubMed ID: 8789434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective gene therapy in an authentic model of Tay-Sachs-related diseases.
    Cachón-González MB; Wang SZ; Lynch A; Ziegler R; Cheng SH; Cox TM
    Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10373-10378. PubMed ID: 16801539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.
    Lahey HG; Webber CJ; Golebiowski D; Izzo CM; Horn E; Taghian T; Rodriguez P; Batista AR; Ellis LE; Hwang M; Martin DR; Gray-Edwards H; Sena-Esteves M
    Mol Ther; 2020 Oct; 28(10):2150-2160. PubMed ID: 32592687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversion of the biochemical defects in murine embryonic Sandhoff neurons using a bicistronic lentiviral vector encoding hexosaminidase alpha and beta.
    Arfi A; Zisling R; Richard E; Batista L; Poenaru L; Futerman AH; Caillaud C
    J Neurochem; 2006 Mar; 96(6):1572-9. PubMed ID: 16441513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of inducible models of Tay-Sachs and related disease.
    Sargeant TJ; Drage DJ; Wang S; Apostolakis AA; Cox TM; Cachón-González MB
    PLoS Genet; 2012 Sep; 8(9):e1002943. PubMed ID: 23028353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.